



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

Last Trade:	20.85
Trade Time:	4:00 PM ET Oct 19, 2017
Change:	0.45 (+2.206%)
Day Range	20.10 - 20.98
52-Week Range	3.20 - 24.45
Volume	1,278,138

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 19, 2017

[Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy](#)

Sep 5, 2017

[Dynavax to Present at Upcoming Investor Conferences](#)

Aug 15, 2017

[Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock](#)

Aug 9, 2017

[Dynavax Prices Public Offering of Common Stock](#)

Aug 8, 2017

[Dynavax Announces Proposed Public Offering of Common Stock](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Jul 10, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)